再鼎医药财报出炉大跌,不及预期还是倒车接人?

格隆汇资讯
Aug 11

在创新药板块热度攀升之际,再鼎医药(NASDAQ: ZLAB / HKEX: 9688)于8月7日发布2025年第二季度业绩。财报显示,公司当季实现总收入1.1亿美元,同比增长9%(固定汇率计算增长10%),管理层重申全年收入指引,并明确 "2025年第四季度实现Non-GAAP经营利润转正"的盈利目标。然而资本市场反应分化:绩后首个交易日,再鼎医药美股股价下跌11.98%,港股同步回调...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10